IDEV(R) Technologies Announces First Patient Enrolled in Multi-Center Clinical Trial of SUPERA(R) PERiph...(U.S. Dr. Rosenfield said. We believe t...),Health

Dr. Garcia added, "Ultimately, through this study, the SUPERA stent could become the new benchmark for stenting infra-inguinal femoral arterial obstructive disease."

Peter Soukas, M.D., Director of Vascular Medicine and the Vascular Laboratories at St. Elizabeth's, enrolled and treated the trial's first patient.

"Our patient had a calcified SFA lesion that was treated thanks to the radial strength and flexibility afforded by the unique woven design of the SUPERA stent," Dr. Soukas said. "I am confident the stent will demonstrate the same resistance to strut fracture and primary patency that has been seen in Europe."

IDEV President and Chief Operating Officer Christopher M. Owens called the enrollment of the first patient "a significant milestone for IDEV Technologies and an opportunity to demonstrate the safety and effectiveness of the unique SUPERA design. I'd like to congratulate all the members of our team on our progress to this point."

About IDEV Technologies, Incorporated

IDEV Technologies, Incorporated (IDEV) is an innovator and developer of next generation medical devices for use in the interventional radiology, vascular surgery and cardiology device marketplace. IDEV is based in Houston, Texas.

    Contact:  Christopher M. Owens, President and COO
              John Dame, Vice President of Finance
              IDEV Technologies, Inc.
              (281) 333-1998